CL2018003141A1 - Polipéptidos de fusión cd40l-fc y sus métodos de uso. - Google Patents

Polipéptidos de fusión cd40l-fc y sus métodos de uso.

Info

Publication number
CL2018003141A1
CL2018003141A1 CL2018003141A CL2018003141A CL2018003141A1 CL 2018003141 A1 CL2018003141 A1 CL 2018003141A1 CL 2018003141 A CL2018003141 A CL 2018003141A CL 2018003141 A CL2018003141 A CL 2018003141A CL 2018003141 A1 CL2018003141 A1 CL 2018003141A1
Authority
CL
Chile
Prior art keywords
cd40l
methods
fusion protein
fusion polypeptides
combined
Prior art date
Application number
CL2018003141A
Other languages
English (en)
Inventor
Manuel Baca
Stacey Drabic
Peter Emtage
Ronald Herbst
Original Assignee
Medimmune Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Llc filed Critical Medimmune Llc
Publication of CL2018003141A1 publication Critical patent/CL2018003141A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Epidemiology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

EN LA PRESENTE SE PROPORCIONA UNA PROTEÍNA DE FUSIÓN CD40L-FC Y MÉTODOS PARA UTILIZAR LA PROTEÍNA DE FUSIÓN EN EL TRATAMIENTO DEL CÁNCER QUE COMPRENDEN ADMINISTRAR LA PROTEÍNA DE FUSIÓN CD40L-FC O LA PROTEÍNA DE FUSIÓN CD40L-FC COMBINADA CON UNO O MÁS INHIBIDORES DE PUNTOS DE CONTROL INMUNITARIO (POR EJEMPLO, UN ANTICUERPO ANTI-CTLA4 O ANTICUERPO ANTI-PD-L1).
CL2018003141A 2016-05-13 2018-11-05 Polipéptidos de fusión cd40l-fc y sus métodos de uso. CL2018003141A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662336129P 2016-05-13 2016-05-13

Publications (1)

Publication Number Publication Date
CL2018003141A1 true CL2018003141A1 (es) 2018-12-28

Family

ID=60267851

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018003141A CL2018003141A1 (es) 2016-05-13 2018-11-05 Polipéptidos de fusión cd40l-fc y sus métodos de uso.

Country Status (18)

Country Link
US (1) US10975155B2 (es)
EP (1) EP3455263A4 (es)
JP (1) JP2019523636A (es)
KR (1) KR20190004319A (es)
CN (1) CN109153729A (es)
AR (1) AR108468A1 (es)
AU (1) AU2017264944A1 (es)
BR (1) BR112018072953A2 (es)
CA (1) CA3022636A1 (es)
CL (1) CL2018003141A1 (es)
CO (1) CO2018013104A2 (es)
IL (1) IL262727A (es)
MA (1) MA44993A (es)
MX (1) MX2018013762A (es)
RU (1) RU2018138703A (es)
SG (1) SG11201809374VA (es)
TW (1) TW201741337A (es)
WO (1) WO2017197231A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010010051A1 (en) * 2008-07-21 2010-01-28 Apogenix Gmbh Tnfsf single chain molecules
HUE046674T2 (hu) 2013-09-11 2020-03-30 Medimmune Ltd B7-H1 elleni antitestek tumorok kezelésére
US11542332B2 (en) 2016-03-26 2023-01-03 Bioatla, Inc. Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof
US11298420B2 (en) * 2016-12-21 2022-04-12 Memgen, Llc Armed oncolytic viruses
WO2018127916A1 (en) 2017-01-05 2018-07-12 Kahr Medical Ltd. A pd1-cd70 fusion protein and methods of use thereof
US11299530B2 (en) 2017-01-05 2022-04-12 Kahr Medical Ltd. SIRP alpha-CD70 fusion protein and methods of use thereof
ES2916217T3 (es) 2017-01-05 2022-06-29 Kahr Medical Ltd Una proteína de fusión SIRP1 ALPHA-41BBL y métodos de uso de la misma
HRP20230937T1 (hr) 2017-01-05 2023-11-24 Kahr Medical Ltd. Pd1-41bbl fuzijski protein i metode korištenja istog
US20220135649A1 (en) * 2019-02-06 2022-05-05 The Regents Of The University Of California Dominant negative cd40l polypeptides
KR20210006301A (ko) * 2019-07-08 2021-01-18 주식회사 프로젠 신규 융합단백질 및 그의 용도
WO2021149945A1 (ko) * 2020-01-23 2021-07-29 주식회사 제넥신 Pd-l1 단백질이 포함된 융합 단백질 및 이의 용도
WO2023088876A1 (en) * 2021-11-16 2023-05-25 Apogenix Ag Multi-specific immune modulators

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0832229T3 (da) * 1995-06-07 2004-05-03 Immunex Corp CD40L-mutein
BR9710264A (pt) * 1996-07-08 1999-08-10 Univ Columbia Aplicações terapéuticas da tecnologia do t-bam (cd40l) para tratar de doenças envolvendo as células do músculo liso
US6774225B2 (en) 1999-04-15 2004-08-10 Hong Kong University Of Science & Technology Antigenized antibody vaccine for foot-and-mouth disease
US20020076406A1 (en) * 2000-07-25 2002-06-20 Leung Shui-On Multivalent target binding protein
JP4660092B2 (ja) 2001-12-21 2011-03-30 イミユネツクス・コーポレイシヨン 組換えポリペプチド
NZ563392A (en) 2005-05-20 2009-12-24 Ablynx Nv Improved Nanobodies(TM) for the treatment of aggregation-mediated disorders
WO2010010051A1 (en) * 2008-07-21 2010-01-28 Apogenix Gmbh Tnfsf single chain molecules
MA41460A (fr) * 2015-02-03 2017-12-12 Oncomed Pharm Inc Agents de liaison à la tnfrsf et leurs utilisations
BR112017023646A2 (pt) * 2015-05-04 2018-07-17 Apogenix Ag proteínas agonistas de receptor de cd40 de cadeia simples

Also Published As

Publication number Publication date
WO2017197231A1 (en) 2017-11-16
TW201741337A (zh) 2017-12-01
MA44993A (fr) 2019-03-20
RU2018138703A (ru) 2020-06-15
CN109153729A (zh) 2019-01-04
BR112018072953A2 (pt) 2019-02-19
JP2019523636A (ja) 2019-08-29
SG11201809374VA (en) 2018-11-29
EP3455263A4 (en) 2020-01-01
US20170327588A1 (en) 2017-11-16
US10975155B2 (en) 2021-04-13
AR108468A1 (es) 2018-08-22
CA3022636A1 (en) 2017-11-16
AU2017264944A1 (en) 2018-12-20
EP3455263A1 (en) 2019-03-20
KR20190004319A (ko) 2019-01-11
IL262727A (en) 2018-12-31
CO2018013104A2 (es) 2018-12-14
MX2018013762A (es) 2019-03-28

Similar Documents

Publication Publication Date Title
CL2018003141A1 (es) Polipéptidos de fusión cd40l-fc y sus métodos de uso.
CL2021000704A1 (es) Anticuerpos contra proteína alfa reguladora de señal y métodos de uso. (divisional de solicitud 668-2019)
CL2018002878A1 (es) Composiciones y anticuerpos anti-tim-3.
CO2018002450A2 (es) Proteínas de fusión de gitrl y usos de las mismas
CL2018002687A1 (es) Proteínas de unión y métodos de uso de las mismas
ECSP19072235A (es) Anticuerpos anti-ILT4 y fragmentos de unión a antígeno
BR112018070183A2 (pt) neoantígenos e métodos de seu uso
PE20170503A1 (es) Proteinas de fusion de interleucina 2/receptor de interleucina-2 alfa y metodos de uso
CL2017002050A1 (es) Uso de plinabulina en combinación con inhibidores de punto de control inmunitario
CO2017000754A2 (es) Anticuerpo monoclonal anti-ctla4 o fragmento de unión a antígeno del mismo, y una composición farmacéutica del mismo
CL2019003093A1 (es) Anticuerpos anti-trem2 y métodos para utilizarlos.
CL2018002998A1 (es) Composiciones que comprenden una coformulación de anticuerpos anti-pd-l1 y anti-ctla-4
EA201891589A1 (ru) Условно активные гетеродимерные полипептиды и способы их применения
CR20170240A (es) Anticuerpos anti-interleucina-33 y sus usos
MX2020004801A (es) Polipeptidos de fusion biespecificos y sus metodos de uso.
CO2017001191A2 (es) Conjugados de fármacos con anticuerpos anti-cdh6
CR20160500A (es) Anticuerpos anti-ox40 y métodos de uso
CL2018003515A1 (es) Anticuerpos anti-gitr y sus usos.
DOP2019000191A (es) Anticuerpos anti-tgf-beta y su uso
CR20160362A (es) Anticuerpos anti-jagged1 y metodos de uso
UY37456A (es) Inmunoglobulinas y sus usos
PH12019501285A1 (en) Antibodies and polypeptides directed against cd127
CL2019002323A1 (es) Anticuerpo dirigido a il-13ra2 y su uso.
ES2721935T3 (es) Anticuerpos anti-BAG3 para uso terapéutico
BR112016029935A2 (pt) ?anticorpos anti-brdu, complexo, formulação farmacêutica e uso de anticorpo?